HEALTH● LOW2h ago · Oct 16, 2026, 6:00 PM
Novartis halts mid-stage trial for kidney drug, Fabhalta, in lupus nephritis
Seeking Alpha Tech · global
Novartis has stopped a mid-stage clinical trial for its kidney drug, Fabhalta, which was being tested for lupus nephritis. This is a development in pharmaceutical research and drug development.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH44m agoNew law aims to stop overdoses with stiffer penalties as 8 states struggle to slow deathsThe Independent WorldHEALTH48m agoN.I.H. Hospital Board Rebukes Kennedy Over New Vaccine Injury ClinicNYT USHEALTH53m agoNurses say technology is making their jobs and patient care worsevtcng.comHEALTH1h agoMental health cannot be ignored in female entrepreneurship programsLa Silla Vacía